title: Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
abstract: The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings. Mycophenolate Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited. We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n=33), myelodysplastic syndrome (MDS) (n=3), acute lymphoblastic leukemia (ALL) (n=20) or chronic myeloid leukemia (n=37) who received CSA/MMF (n=26) or CSA/MTX (n=67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings. No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD. Time to myeloid recovery was significantly shorter in patients who received CSA/MMF. We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings.
authors.affiliation: Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Duesseldorf, Germany, Moorenstrasse 5, Duesseldorf, Germany. FTIMI@aol.com
authors.forename: F
authors.initials: F
authors.lastname: Neumann
authors.forename: T
authors.initials: T
authors.lastname: Graef
authors.forename: C
authors.initials: C
authors.lastname: Tapprich
authors.forename: M
authors.initials: M
authors.lastname: Vaupel
authors.forename: U
authors.initials: U
authors.lastname: Steidl
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: R
authors.initials: R
authors.lastname: Fenk
authors.forename: A
authors.initials: A
authors.lastname: Hinke
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
mesh_terms: D000293:Adolescent; D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006680:HLA Antigens; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007938:Leukemia / Q000401:mortality / Q000628:therapy; D019520:Living Donors; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy; D012008:Recurrence; D012189:Retrospective Studies; D035781:Siblings; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000379:methods; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D008727:Methotrexate